drugset / Trial / NCT04026321
Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US
Phase 1
Completed
40 enrolled
Livzon Pharmaceutical Group Inc.
Keystone Bioanalytical, Inc. · collabPalm Beach CRO · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a single-center, double-blind, single-dose escalation study in healthy volunteers.
Timeline
- Start
- 2018-10-03
- Primary completion
- 2018-12-06
- Completion
- 2018-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SQ001 | Unknown | 125 ml | Intravenous |
| Subject | SQ001 | Unknown | 250 ml | Intravenous |
| Subject | SQ001 | Unknown | 500 ml | Intravenous |
| Subject | SQ001 | Unknown | 625 ml | Intravenous |